首页> 外文OA文献 >microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.
【2h】

microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer.

机译:与microRNA相关的进展途径和潜在的治疗靶标,通过整合的mRNA和microRNA表达谱在乳腺癌中鉴定。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

microRNA expression profiling plays an emerging role in cancer classification and identification of therapeutic strategies. In this study, we have evaluated the benefits of a joint microRNA-mRNA analysis in breast cancer. Matched mRNA and microRNA global expression profiling was conducted in a well-annotated cohort of 207 cases with complete 10-year follow-up. Penalized Cox regression including microRNA expression, mRNA expression, and clinical covariates was used to identify microRNAs associated with distant relapse-free survival (DRFS) that provide independent prognostic information, and are not simply surrogates of previously identified prognostic covariates. Penalized regression was chosen to prevent overfitting. Furthermore, microRNA-mRNA relationships were explored by global expression analysis, and exploited to validate results in several published cohorts (n = 592 with DRFS, n = 1,050 with recurrence-free survival). Four microRNAs were independently associated with DRFS in estrogen receptor (ER)-positive (3 novel and 1 known; miR-128a) and 6 in ER-negative (5 novel and 1 known; miR-210) cases. Of the latter, miR-342, -27b, and -150 were prognostic also in triple receptor-negative tumors. Coordinated expression of predicted target genes and prognostic microRNAs strengthened these results, most significantly for miR-210, -128a, and -27b, whose targets were prognostic in meta-analysis of several cohorts. In addition, miR-210 and -128a showed coordinated expression with their cognate pri-microRNAs, which were themselves prognostic in independent cohorts. Our integrated microRNA-mRNA global profiling approach has identified microRNAs independently associated with prognosis in breast cancer. Furthermore, it has validated known and predicted microRNA-target interactions, and elucidated their association with key pathways that could represent novel therapeutic targets.
机译:microRNA表达谱在癌症分类和治疗策略确定中起着新兴作用。在这项研究中,我们评估了联合microRNA-mRNA分析在乳腺癌中的益处。在207例病例注释充分的队列中进行了匹配的mRNA和microRNA整体表达谱分析,并进行了为期10年的随访。受罚的Cox回归(包括microRNA表达,mRNA表达和临床协变量)用于鉴定与远距无复发生存期(DRFS)相关的microRNA,它们提供独立的预后信息,而不仅仅是先前鉴定的预后协变量的替代物。选择惩罚式回归以防止过度拟合。此外,通过全局表达分析探索了microRNA与mRNA的关系,并利用其来验证已发表的多个队列中的结果(DRFS中n = 592,无复发生存期n = 1,050)。在雌激素受体(ER)阳性(3例,已知1例; miR-128a)中,有4个microRNA与DRFS独立相关;在ER阴性(5例,已知1例; miR-210)中,有6个microRNA与DRFS独立相关。在后者中,miR-342,-27b和-150在三联受体阴性肿瘤中也预后。预测靶基因和预后性microRNA的协同表达加强了这些结果,其中最显着的是miR-210,-128a和-27b,它们的靶标在多个队列的荟萃分析中具有预后性。此外,miR-210和-128a与它们的同源pri-microRNAs协调表达,它们本身在独立队列中是预后的。我们整合的microRNA-mRNA全球分析方法已鉴定出与乳腺癌预后独立相关的microRNA。此外,它已经验证了已知的和预测的microRNA-靶标相互作用,并阐明了它们与可能代表新治疗靶标的关键途径的关联。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号